Alliqua pulls in $20M to support hydrogel wound care biz

Pennsylvania wound-care specialist Alliqua ($ALQA) pulled in $15 million from a private funding round and another $5.3 million from the exercise of warrants, giving the company a $20.3 million windfall overall. Alliqua intends to funnel the cash into its capital coffers, and in an April 15 release the company also said it is looking to expand its technology lineup through possible acquisitions. Alliqua currently markets its line of hydrogel advanced wound care products, which Seeking Alpha reported earlier this month could grow the company's revenues to $35 million within three years. Release | Article

Suggested Articles

J&J figures its partner Genmab owes a share of Darzalex Faspro royalties to Halozyme for its subcutaneous delivery tech. Genmab doesn't agree.

Bexson Biomedical and Stevanato Group teamed up to develop a ketamine pump that may help patients better manage pain at home.

Australia's University of New South Wales and Uka Tarsadia University in India will join forces to explore contact lenses for ocular drug delivery.